On patenting human genes, the evidence favors Myriad

The following is an excerpt.

The conventional shorthand for the Association for Molecular Pathology v. Myriad, Inc.case, argued before the Supreme Court on April 15, 2013, is that it is a dispute about the patentability of human genes. This shorthand is misleading. No one suggests that genes, as they appear in the human body, are subject to patent law—and the consequent restrictions, fees and exclusive licenses that patentees may choose to apply. A less misleading, though less beguiling, characterization of the dispute would cast it as considering selected human genetic tools.

Read the full post here: On Patenting Human Genes, the Evidence Favors Myriad 

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: What are mRNA COVID-19 vaccines and how do they work?

Infographic: What are mRNA COVID-19 vaccines and how do they work?

As of 1 December 2020, thirteen vaccines have reached the final stage of testing: where they are being given to ...
favicon

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend